As more centers begin to switch patients from reference infliximab to biosimilar options, patients who have benefitted from rapid infusions of the reference product may want to continue to receive time-saving infusions that reduce the burden of lengthy visits to infusion centers.
As more centers begin to switch patients from reference infliximab to biosimilar options, patients who have benefitted from rapid infusions of the reference product may want to continue to receive time-saving infusions that reduce the burden of lengthy visits to infusion centers.
A new study sought to evaluate the safety and outcomes of continuing rapid infusion protocols after a switch to biosimilar infliximab.
In a healthcare system that switched all eligible patients with inflammatory bowel disease (IBD) to CT-P13 (Inflectra) from the reference, all patients in the switch cohort (n = 76) who had been receiving rapid infusions of 30 minutes each were compared with a parallel cohort of patients who had received the biosimilar since initiating therapy (n = 44).
Baseline characteristics were comparable across the groups, with the exceptions of higher immunomodulator use among the maintenance cohort and a longer duration of therapy among the switch cohort. No changes were made to patients’ premedications or infusion rates. Patients were prospectively assessed for adverse events (AEs), disease activity, and drug levels.
Baseline infliximab levels before the switch were subtherapeutic in 23% of patients and supratherapeutic in 30%. During a median follow-up of 2 infliximab infusions after the switch, the investigators found no significant AEs, including infusion-related reactions, associated with rapid infusion of the biosimilar.
The authors write that rapid infusion continued through a switch to biosimilar infliximab appears to be safe and effective, and they add that switching also represents an opportunity for physicians to reassess patients’ disease activity and infliximab trough levels to inform clinical decision making.
Previous studies of rapid infusion protocols in other disease states with other biosimilars have also demonstrated that patients can continue to receive rapid infusions after a switch. A 2017 study in patients receiving rituximab showed that patients could be safely switched from the reference product to a rituximab biosimilar without reverting to slower infusion rates.
Reference
Srinivasan A, van Langenberg DR, Haar G, Milller C, Rodrigues B. Rapid 30-minute infliximab infusion protocols when switching inflammatory bowel disease (IBD) patients from originator to biosimilar infliximab. Presented at: Digestive Disease Week 2019; San Diego, CA; May 18-21, 2019. Abstract Su1847.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD
March 15th 2025A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.